Author | Hannah Slater

Articles

Novel PSMA-targeted radioligand therapy shows promise in mCRPC

June 24, 2020

Article

177Lu-PSMA-617, an investigational radioligand therapy, showed stronger clinical activity than cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.